X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2109) 2109
Publication (304) 304
Book Review (28) 28
Book Chapter (18) 18
Dissertation (5) 5
Conference Proceeding (3) 3
Magazine Article (2) 2
Book / eBook (1) 1
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lapatinib (1773) 1773
humans (1292) 1292
index medicus (1262) 1262
oncology (1198) 1198
female (977) 977
trastuzumab (949) 949
breast cancer (948) 948
breast neoplasms - drug therapy (708) 708
her2 (530) 530
cancer (505) 505
breast neoplasms - pathology (449) 449
chemotherapy (443) 443
receptor, erbb-2 - metabolism (435) 435
antineoplastic agents - therapeutic use (377) 377
middle aged (363) 363
skin and connective tissue diseases (351) 351
receptor, erbb-2 - antagonists & inhibitors (349) 349
antineoplastic combined chemotherapy protocols - therapeutic use (321) 321
breast neoplasms - metabolism (312) 312
metastasis (311) 311
aged (304) 304
adult (303) 303
therapy (300) 300
open-label (298) 298
cell line, tumor (296) 296
care and treatment (289) 289
quinazolines - administration & dosage (289) 289
animals (270) 270
growth-factor receptor (262) 262
quinazolines - therapeutic use (249) 249
treatment outcome (247) 247
pharmacology & pharmacy (246) 246
tyrosine kinase inhibitor (246) 246
quinazolines - pharmacology (241) 241
survival (239) 239
epidermal growth factor (232) 232
antineoplastic agents - pharmacology (221) 221
pertuzumab (215) 215
expression (214) 214
research (214) 214
capecitabine (213) 213
receptor, erbb-2 - genetics (211) 211
antineoplastic agents (210) 210
medicine & public health (209) 209
phase-ii (208) 208
breast neoplasms - genetics (204) 204
adjuvant chemotherapy (197) 197
breast-cancer (196) 196
antimitotic agents (186) 186
resistance (184) 184
brain metastases (182) 182
lapatinib plus capecitabine (180) 180
analysis (178) 178
article (177) 177
drug therapy (177) 177
egfr (176) 176
phase-ii trial (175) 175
monoclonal-antibody (169) 169
tumors (167) 167
combination (160) 160
hematology, oncology and palliative medicine (159) 159
mice (159) 159
health aspects (149) 149
protein kinase inhibitors - pharmacology (149) 149
cancer therapies (146) 146
disease-free survival (146) 146
multicenter (146) 146
neoplasms (144) 144
drug resistance, neoplasm (143) 143
prognosis (143) 143
receptor (141) 141
growth (140) 140
male (137) 137
metastatic breast-cancer (137) 137
protein kinase inhibitors - therapeutic use (136) 136
kinases (135) 135
erbb-2 protein (134) 134
quinazolines - adverse effects (133) 133
cell biology (132) 132
metastatic breast cancer (130) 130
receptor, epidermal growth factor - antagonists & inhibitors (129) 129
clinical trials (127) 127
efficacy (126) 126
cell lung-cancer (125) 125
brain neoplasms - secondary (124) 124
tyrosine (123) 123
trial (122) 122
breast neoplasms - mortality (121) 121
activation (118) 118
antibodies, monoclonal, humanized - therapeutic use (118) 118
cell proliferation - drug effects (118) 118
neoplasm metastasis (118) 118
antineoplastic combined chemotherapy protocols - adverse effects (116) 116
signal transduction - drug effects (116) 116
erbb2 (115) 115
gefitinib (115) 115
antibodies, monoclonal, humanized (114) 114
molecular targeted therapy (114) 114
trastuzumab resistance (114) 114
neoadjuvant therapy (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2054) 2054
French (38) 38
German (16) 16
Czech (6) 6
Polish (6) 6
Chinese (4) 4
Japanese (4) 4
Spanish (4) 4
Hungarian (2) 2
Slovenian (2) 2
Turkish (2) 2
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical and Biophysical Research Communications, ISSN 0006-291X, 09/2018, Volume 503, Issue 2, pp. 677 - 683
Breast cancer is most frequently diagnosed cancer and fifth leading cause of death in women. About 20–30% of all breast cancers overexpress HER2/neu receptors.... 
PEGylated liposomes | Lapatinib | Chorioallantoic membrane | HER2 receptor | THERAPEUTICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | TOXICITY | CHEMOTHERAPY | BREAST-CANCER | BIOPHYSICS | CLINICAL-IMPLICATIONS | INHIBITOR | Apoptosis - drug effects | Humans | Receptor, ErbB-2 - metabolism | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Cardiotoxicity - etiology | Antineoplastic Agents - administration & dosage | Lapatinib - toxicity | Antineoplastic Agents - toxicity | Breast Neoplasms - metabolism | Lapatinib - pharmacology | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Cardiotoxicity - prevention & control | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Lapatinib - therapeutic use | Breast Neoplasms - drug therapy | Chick Embryo | Protein Kinase Inhibitors - administration & dosage | Liposomes - chemistry | Animals | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Kinase Inhibitors - toxicity | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Lapatinib - administration & dosage | Antimitotic agents | Care and treatment | Epidermal growth factor | Polyethylene glycol | Analysis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2073 - 2073
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2017, Volume 35, Issue 27, pp. 3089 - 3091
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 07/2018, Volume 34, Issue 1, pp. 148 - 162.e7
Targeting HER2 is effective in 24% of amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the... 
trastuzumab | targeted therapy | rapid autopsy | colorectal cancer | clonal evolution | HER2 amplification | lapatinib | liquid biopsy | ctDNA | resistance | BREAST-CANCER | HETEROGENEITY | PIK3CA MUTATIONS | THERAPY | AMPLIFICATION | SOLID TUMORS | GENE | ONCOLOGY | ACQUIRED-RESISTANCE | EGFR BLOCKADE | PATHOLOGICAL COMPLETE RESPONSE | CELL BIOLOGY | Predictive Value of Tests | ras Proteins - genetics | Liquid Biopsy | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Protein Kinase Inhibitors - adverse effects | Time Factors | DNA Mutational Analysis | Clinical Decision-Making | Colorectal Neoplasms - drug therapy | Female | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Tumor Cells, Cultured | Liver Neoplasms - secondary | Lapatinib - adverse effects | Liver Neoplasms - genetics | Risk Factors | Liver Neoplasms - drug therapy | Trastuzumab - adverse effects | Mice, Transgenic | Treatment Outcome | Colorectal Neoplasms - diagnostic imaging | Trastuzumab - administration & dosage | Mice, SCID | Adenocarcinoma - drug therapy | Liver Neoplasms - diagnostic imaging | Adenocarcinoma - secondary | Disease Progression | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Italy | Mice, Inbred NOD | Adenocarcinoma - diagnostic imaging | Colorectal Neoplasms - pathology | Lapatinib - administration & dosage | Genetic research | Genetic aspects | Metastasis | Analysis | Colorectal cancer | Cancer
Journal Article
Journal Article
CANCER BIOLOGY & THERAPY, ISSN 1538-4047, 05/2011, Volume 11, Issue 9, pp. 793 - 800
The antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are approved by the FDA for the treatment of HER2-overexpressing breast cancer. These... 
ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR-RECEPTOR | LAPATINIB RESISTANCE | lapatinib | MONOCLONAL-ANTIBODY | TRASTUZUMAB RESISTANCE | SOMATIC MUTATIONS | trastuzumab | tyrosine kinase inhibitors | CELL LUNG-CANCER | ONCOLOGY | HER2 (ERBB2) | METASTATIC BREAST-CANCER | DUAL PI3K/MTOR INHIBITOR | antibodies | drug resistance | DEPENDENT ACTIVATION
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2018, Volume 168, Issue 3, pp. 631 - 638
Journal Article
NEURO-ONCOLOGY, ISSN 1522-8517, 05/2019, Volume 21, Issue 5, pp. 659 - 668
Background. Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following... 
SURVIVAL | CRITERIA | TUMOR BIOLOGY | TRASTUZUMAB | PHASE-III | lapatinib | breast cancer | CLINICAL NEUROLOGY | stereotactic radiosurgery | WOMEN | NERVOUS-SYSTEM METASTASES | ONCOLOGY | RADIATION NECROSIS | brain metastasis | HER2 | LAPATINIB PLUS CAPECITABINE | INHIBITOR
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2011, Volume 29, Issue 20, pp. 3835 - 3835
Journal Article
ONCOLOGY-NEW YORK, ISSN 0890-9091, 11/2015, Volume 29, Issue 11, pp. 797 - 797
Journal Article
Cellular and Molecular Life Sciences, ISSN 1420-682X, 3/2019, Volume 76, Issue 6, pp. 1185 - 1199
Receptor tyrosine kinases (RTKs) play key roles in various aspects of cell biology, including cell-to-cell communication, proliferation and differentiation,... 
Life Sciences | Biomedicine, general | Biochemistry, general | Life Sciences, general | Cell-based assay | Lapatinib | Receptor tyrosine kinases | TEV protease | Split TEV recruitment assay | Cell Biology | BIOCHEMISTRY & MOLECULAR BIOLOGY | I RECEPTOR | FAMILY | CELL BIOLOGY | BREAST-CANCER | INSULIN | EGFR LIGANDS | EPIDERMAL-GROWTH-FACTOR | PROTEIN-PROTEIN INTERACTIONS | MULTITARGETED INHIBITORS | BINDING | ERBB RECEPTORS | A549 Cells | Reproducibility of Results | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Humans | ErbB Receptors - genetics | Rats | Biological Assay - methods | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | PC12 Cells | Pyrimidines - metabolism | src Homology Domains | Lapatinib - pharmacology | Animals | Lapatinib - metabolism | Receptor Protein-Tyrosine Kinases - genetics | GRB2 Adaptor Protein - genetics | Protein Binding - drug effects | Cell Line, Tumor | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Acrylamides - metabolism | GRB2 Adaptor Protein - metabolism | Acrylamides - pharmacology | Tyrosine | Epidermal growth factor | Proteases | Detectors | Phenols | Psychotherapy | Cells | Phosphotyrosine | Homeostasis | High-throughput screening | Homology | Antagonists | Neurodevelopmental disorders | Cell interactions | Kinases | Assaying | Recruitment | Proteins | Genetic code | Coding | Growth factors | Adaptor proteins | Cell survival | Hepatocyte growth factor | ErbB protein | Adapters | Pharmacology | Insulin | Grb2 protein | Domains | Ligands | Receptor mechanisms | Biosensors | Adapter proteins | Cancer | Index Medicus | Original
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 06/2018, Volume 35, Issue 6, pp. 122 - 14
Purpose An item response theory (IRT) pharmacometric framework is presented to characterize Functional Assessment of Cancer Therapy-Breast (FACT-B) data in... 
ado-trastuzumab emtansine | capecitabine | nonlinear mixed effects | lapatinib | kadcyla | T-DM1 | NONMEM | FACT-B | VALIDATION | TRANSLATION | CHEMISTRY, MULTIDISCIPLINARY | MISSING-DATA | MODELS | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | FUNCTIONAL-ASSESSMENT | TRASTUZUMAB EMTANSINE T-DM1 | ADVERSE EVENTS | Trastuzumab - therapeutic use | Maytansine - analogs & derivatives | Humans | Capecitabine - pharmacology | Lapatinib - therapeutic use | Treatment Outcome | Capecitabine - therapeutic use | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Maytansine - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Lapatinib - pharmacology | Young Adult | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Models, Biological | Adult | Female | Trastuzumab - pharmacology | Longitudinal Studies | Patient Reported Outcome Measures | Antimitotic agents | Care and treatment | Cancer patients | Patient outcomes | Analysis | Breast cancer | Metastasis | Antineoplastic agents | Breast | Mathematical models | Exposure | Pharmacology | Patients | Trastuzumab | Metastases | Cancer | Research Paper | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
BMB Reports, ISSN 1976-6696, 2018, Volume 51, Issue 12, pp. 660 - 665
Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers.... 
Lapatinib | Drug resistance | HER2 | Gastric cancer | AUY922
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 04/2015, Volume 107, Issue 4
Journal Article